Avaliação da eficácia da proteína miriostelada-3 (smp-3) de leishmania amazonensis como candidata à vacina contra a leishmaniose visceral

• Ano de defesa: 2018
• Autor(a) principal: Marcelo Perdigão de Oliveira
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Minas Gerais; Brasil; MEDICINA - FACULDADE DE MEDICINA; Programa de Pós-Graduação em Ciências da Saúde - Infectologia e Medicina Tropical; UFMG
• Palavras-chave em Português: Leishmania infantum; Proteínas recombinantes; Vacinas; Bioinformática; Leishmaniose; Proteínas Recombinantes; Biologia Computacional
• Link de acesso: http://hdl.handle.net/1843/47248

In a proteomics approach performed using Leishmania amazonensis, parasite proteins showed either an increase or a decrease in their expression content during extensive in vitro cultivation and were related to the survival and infectivity of the parasites, respectively. In the present study, a computational screening was performed to predict virulence factors among these molecules. Three proteins were selected, one of which presented no structural homology to human proteins. This candidate, namely small myristoylated protein-3 (SMP3), was cloned and its recombinant version (rSMP-3) was used to stimulate peripheral blood mononuclear cells (PBMCs) from healthy subjects living in an endemic area of leishmaniasis and from visceral leishmaniasis (VL) patients. Results showed high interferon-γ (IFN-γ) production and low levels of interleukin 10 (IL-10) in the cell supernatants. An in vivo experiment was performed on BALB/c mice, which were immunized with rSMP-3/saponin and later challenged with Leishmania infantum promastigotes. The rSMP-3/saponin combination induced high production of protein-specific IFN-γ, IL-12, and GM-CSF by the spleen cells of the immunized mice. This pattern was associated with protection, which was characterized by a significant reduction in the parasite load in distinct organs of the immunized animals. Altogether, these results revealed that this new virulence factor is immunogenic in both mice and humans and have proven its protective efficacy against murine VL.